Skip to main content
Erschienen in: Indian Journal of Thoracic and Cardiovascular Surgery 1/2018

18.10.2017 | Review Article

Non-invasive approaches for lung cancer diagnosis

verfasst von: Aditi Mehta, Guillermo Barreto

Erschienen in: Indian Journal of Thoracic and Cardiovascular Surgery | Sonderheft 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. The case-fatality rate of lung cancer remains exceptionally high at 95% despite numerous medical advancements in therapeutic strategies in the last decades. However, patients diagnosed at Stage I are commonly curable and have a 5-year survival rate of 50–80%. Unfortunately, delayed diagnosis of lung cancer has been unavoidable and is an important factor in the overall outcome of treatment. Accordingly, screening of high-risk individuals is likely to have hugely beneficial outcomes for patient survival. Current screening approaches include low-dose computed tomography and chest X-ray. Recently, alternative approaches for lung cancer screening have been developed including analysis of biomarkers, including DNA, RNA, proteins, and antibodies in blood, sputum, bronchoalveolar lavage (BAL), and breath. Biomarker analysis would also provide critical information regarding tumor growth pattern, cells of origin of tumor, subtype of lung cancer, and/or drug metabolism as well as monitor patient prognosis. Novel non-invasive lung cancer diagnostic strategies could improve and complement the success of CT-scan and chest X-ray.
Literatur
1.
2.
Zurück zum Zitat Giangreco A, Groot KR, Janes SM. Lung cancer and lung stem cells: strange bedfellows? Am J Respir Crit Care Med. 2007;175:547–53.CrossRefPubMed Giangreco A, Groot KR, Janes SM. Lung cancer and lung stem cells: strange bedfellows? Am J Respir Crit Care Med. 2007;175:547–53.CrossRefPubMed
5.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013. Available from: https://www.globocan.iarc.fr. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013. Available from: https://​www.​globocan.​iarc.​fr.
7.
Zurück zum Zitat Mehta A, Dobersch S, Romero-Olmedo AJ, Barreto G. Epigenetics in lung cancer diagnosis and therapy. Cancer Metastasis Rev. 2015;34:229–41.CrossRefPubMed Mehta A, Dobersch S, Romero-Olmedo AJ, Barreto G. Epigenetics in lung cancer diagnosis and therapy. Cancer Metastasis Rev. 2015;34:229–41.CrossRefPubMed
9.
Zurück zum Zitat Pass HI CD JD, Minna JD, Scagliotti GV, Turrisi AT Principles and Practice of Lung Cancer . The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC) Lippincott Williams and Wilkins, a Wolters Kluwer business: Alphen aan den Rijn, The Netherlands . 2010. Pass HI CD JD, Minna JD, Scagliotti GV, Turrisi AT Principles and Practice of Lung Cancer . The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC) Lippincott Williams and Wilkins, a Wolters Kluwer business: Alphen aan den Rijn, The Netherlands . 2010.
10.
Zurück zum Zitat Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e278S–313S.CrossRefPubMed Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e278S–313S.CrossRefPubMed
11.
Zurück zum Zitat Peters GJ, Avan A, Ruiz MG, et al. Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer. Anticancer Res. 2014;34:435–42.PubMed Peters GJ, Avan A, Ruiz MG, et al. Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer. Anticancer Res. 2014;34:435–42.PubMed
12.
Zurück zum Zitat Chu Q, Vincent M, Logan D, Mackay JA, Evans WK. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung cancer. 2005;50:355–74.CrossRefPubMed Chu Q, Vincent M, Logan D, Mackay JA, Evans WK. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung cancer. 2005;50:355–74.CrossRefPubMed
13.
Zurück zum Zitat Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Health Technol Assess. 2001;5:1–195.CrossRef Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Health Technol Assess. 2001;5:1–195.CrossRef
14.
15.
Zurück zum Zitat Burdett SS, Stewart LA, Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev. 2007;3:CD006157. Burdett SS, Stewart LA, Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev. 2007;3:CD006157.
16.
Zurück zum Zitat Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.CrossRefPubMedPubMedCentral Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Corner J, Hopkinson J, Fitzsimmons D, Barclay S, Muers M. Is late diagnosis of lung cancer inevitable? Interview study of patients' recollections of symptoms before diagnosis. Thorax. 2005;60:314–9.CrossRefPubMedPubMedCentral Corner J, Hopkinson J, Fitzsimmons D, Barclay S, Muers M. Is late diagnosis of lung cancer inevitable? Interview study of patients' recollections of symptoms before diagnosis. Thorax. 2005;60:314–9.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. New Eng J Med. 2011;365:395–409.CrossRefPubMed Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. New Eng J Med. 2011;365:395–409.CrossRefPubMed
22.
Zurück zum Zitat Yousaf-Khan U, van der Aalst C, de Jong PA, et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. Thorax. 2017;72:48–56.CrossRefPubMed Yousaf-Khan U, van der Aalst C, de Jong PA, et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. Thorax. 2017;72:48–56.CrossRefPubMed
23.
Zurück zum Zitat Horeweg N, van der Aalst CM, Vliegenthart R, et al. Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur Respir J. 2013;42:1659–67.CrossRefPubMed Horeweg N, van der Aalst CM, Vliegenthart R, et al. Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur Respir J. 2013;42:1659–67.CrossRefPubMed
26.
Zurück zum Zitat Eramo A, Haas TL, De Maria R. Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene. 2010;29:4625–35.CrossRefPubMed Eramo A, Haas TL, De Maria R. Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene. 2010;29:4625–35.CrossRefPubMed
27.
30.
31.
32.
Zurück zum Zitat Alama A, Truini A, Coco S, Genova C, Grossi F. Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. Drug Discov Today. 2014;19:1671–6.CrossRefPubMed Alama A, Truini A, Coco S, Genova C, Grossi F. Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. Drug Discov Today. 2014;19:1671–6.CrossRefPubMed
33.
Zurück zum Zitat Calabuig-Farinas S, Jantus-Lewintre E, Herreros-Pomares A, Camps C. Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? Transl Lung Cancer Res. 2016;5:466–82.CrossRefPubMedPubMedCentral Calabuig-Farinas S, Jantus-Lewintre E, Herreros-Pomares A, Camps C. Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? Transl Lung Cancer Res. 2016;5:466–82.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013;14:18925–58.CrossRefPubMedPubMedCentral Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013;14:18925–58.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Birse CE, Lagier RJ, FitzHugh W, et al. Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium. Clin Proteomics. 2015;12:18.CrossRefPubMedPubMedCentral Birse CE, Lagier RJ, FitzHugh W, et al. Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium. Clin Proteomics. 2015;12:18.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Oshita F, Nomura I, Yamada F, Kato F, Tanaka F, Noda F. Detection of K-ras mutations of bronchoalveolar lavage fluid cells aids the diagnosis of lung cancer in small pulmonary lesions. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999;5:617–20. Oshita F, Nomura I, Yamada F, Kato F, Tanaka F, Noda F. Detection of K-ras mutations of bronchoalveolar lavage fluid cells aids the diagnosis of lung cancer in small pulmonary lesions. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999;5:617–20.
39.
Zurück zum Zitat Risse EK, van't Hof MA, Laurini RN, Vooijs PG. Sputum cytology by the Saccomanno method in diagnosing lung malignancy. Diagn Cytopathol. 1985;1:286–91.CrossRefPubMed Risse EK, van't Hof MA, Laurini RN, Vooijs PG. Sputum cytology by the Saccomanno method in diagnosing lung malignancy. Diagn Cytopathol. 1985;1:286–91.CrossRefPubMed
40.
Zurück zum Zitat Roby TJ, Swan GE, Sorensen KW, Hubbard GA, Schumann GB. Discriminant analysis of lower respiratory tract components associated with cigarette smoking, based on quantitative sputum cytology. Acta Cytol. 1990;34:147–54.PubMed Roby TJ, Swan GE, Sorensen KW, Hubbard GA, Schumann GB. Discriminant analysis of lower respiratory tract components associated with cigarette smoking, based on quantitative sputum cytology. Acta Cytol. 1990;34:147–54.PubMed
41.
Zurück zum Zitat Mehta AC, Marty JJ, Lee FY. Sputum cytology. Clin Chest Med. 1993;14:69–85.PubMed Mehta AC, Marty JJ, Lee FY. Sputum cytology. Clin Chest Med. 1993;14:69–85.PubMed
42.
Zurück zum Zitat Baryshnikova E, Destro A, Infante MV, et al. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program. Clin Cancer Res. 2008;14:1913–9.CrossRefPubMed Baryshnikova E, Destro A, Infante MV, et al. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program. Clin Cancer Res. 2008;14:1913–9.CrossRefPubMed
43.
Zurück zum Zitat Destro A, Bianchi P, Alloisio M, et al. K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung cancer. 2004;44:23–32.CrossRefPubMed Destro A, Bianchi P, Alloisio M, et al. K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung cancer. 2004;44:23–32.CrossRefPubMed
44.
Zurück zum Zitat Keohavong P, Gao WM, Zheng KC, et al. Detection of K-ras and p53 mutations in sputum samples of lung cancer patients using laser capture microdissection microscope and mutation analysis. Anal Biochem. 2004;324:92–9.CrossRefPubMed Keohavong P, Gao WM, Zheng KC, et al. Detection of K-ras and p53 mutations in sputum samples of lung cancer patients using laser capture microdissection microscope and mutation analysis. Anal Biochem. 2004;324:92–9.CrossRefPubMed
45.
Zurück zum Zitat Minh Tdo C, Blake DR, Galassetti PR. The clinical potential of exhaled breath analysis for diabetes mellitus. Diabetes Res Clin Pract. 2012;97:195–205.CrossRefPubMed Minh Tdo C, Blake DR, Galassetti PR. The clinical potential of exhaled breath analysis for diabetes mellitus. Diabetes Res Clin Pract. 2012;97:195–205.CrossRefPubMed
46.
Zurück zum Zitat Krisher S, Riley A, Mehta K. Designing breathalyser technology for the developing world: how a single breath can fight the double disease burden. J Med Eng Technol. 2014;38:156–63.CrossRefPubMed Krisher S, Riley A, Mehta K. Designing breathalyser technology for the developing world: how a single breath can fight the double disease burden. J Med Eng Technol. 2014;38:156–63.CrossRefPubMed
47.
Zurück zum Zitat Boedeker E, Friedel G, Walles T. Sniffer dogs as part of a bimodal bionic research approach to develop a lung cancer screening. Interact Cardiovasc Thorac Surg. 2012;14:511–5.CrossRefPubMedPubMedCentral Boedeker E, Friedel G, Walles T. Sniffer dogs as part of a bimodal bionic research approach to develop a lung cancer screening. Interact Cardiovasc Thorac Surg. 2012;14:511–5.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Lippi G, Cervellin G. Canine olfactory detection of cancer versus laboratory testing: myth or opportunity? Clin Chem Lab Med. 2012;50:435–9.PubMed Lippi G, Cervellin G. Canine olfactory detection of cancer versus laboratory testing: myth or opportunity? Clin Chem Lab Med. 2012;50:435–9.PubMed
50.
Zurück zum Zitat Di Natale C, Macagnano A, Martinelli E, et al. Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors. Biosens Bioelectron. 2003;18:1209–18.CrossRefPubMed Di Natale C, Macagnano A, Martinelli E, et al. Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors. Biosens Bioelectron. 2003;18:1209–18.CrossRefPubMed
51.
Zurück zum Zitat Dragonieri S, Annema JT, Schot R, et al. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung cancer. 2009;64:166–70.CrossRefPubMed Dragonieri S, Annema JT, Schot R, et al. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung cancer. 2009;64:166–70.CrossRefPubMed
52.
Zurück zum Zitat Barash O, Peled N, Tisch U, Bunn PA Jr, Hirsch FR, Haick H. Classification of lung cancer histology by gold nanoparticle sensors. Nanomedicine. 2012;8:580–9.CrossRefPubMed Barash O, Peled N, Tisch U, Bunn PA Jr, Hirsch FR, Haick H. Classification of lung cancer histology by gold nanoparticle sensors. Nanomedicine. 2012;8:580–9.CrossRefPubMed
54.
Zurück zum Zitat Nardi-Agmon I, Abud-Hawa M, Liran O, et al. Exhaled breath analysis for monitoring response to treatment in advanced lung cancer. J Thorac Oncol. 2016;11:827–37.CrossRefPubMed Nardi-Agmon I, Abud-Hawa M, Liran O, et al. Exhaled breath analysis for monitoring response to treatment in advanced lung cancer. J Thorac Oncol. 2016;11:827–37.CrossRefPubMed
55.
Zurück zum Zitat Chen JL, Chen JR, Huang FF, Tao GH, Zhou F, Tao YJ. Analysis of p16 gene mutations and their expression using exhaled breath condensate in non-small-cell lung cancer. Oncol Lett. 2015;10:1477–80.CrossRefPubMedPubMedCentral Chen JL, Chen JR, Huang FF, Tao GH, Zhou F, Tao YJ. Analysis of p16 gene mutations and their expression using exhaled breath condensate in non-small-cell lung cancer. Oncol Lett. 2015;10:1477–80.CrossRefPubMedPubMedCentral
56.
Zurück zum Zitat Xiao P, Chen JR, Zhou F, et al. Methylation of P16 in exhaled breath condensate for diagnosis of non-small cell lung cancer. Lung cancer. 2014;83:56–60.CrossRefPubMed Xiao P, Chen JR, Zhou F, et al. Methylation of P16 in exhaled breath condensate for diagnosis of non-small cell lung cancer. Lung cancer. 2014;83:56–60.CrossRefPubMed
57.
Zurück zum Zitat Mozzoni P, Banda I, Goldoni M, et al. Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer. Biomarkers. 2013;18:679–86.CrossRefPubMed Mozzoni P, Banda I, Goldoni M, et al. Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer. Biomarkers. 2013;18:679–86.CrossRefPubMed
58.
Zurück zum Zitat Mehta A, Cordero J, Dobersch S, et al. Non-invasive lung cancer diagnosis by detection of GATA6 and NKX2-1 isoforms in exhaled breath condensate. EMBO Mol Med. 2016;8:1380–9.CrossRefPubMedPubMedCentral Mehta A, Cordero J, Dobersch S, et al. Non-invasive lung cancer diagnosis by detection of GATA6 and NKX2-1 isoforms in exhaled breath condensate. EMBO Mol Med. 2016;8:1380–9.CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Bach PB, Silvestri GA, Hanger M, Jett JR. American College of Chest Physicians. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:69S–77S.CrossRefPubMed Bach PB, Silvestri GA, Hanger M, Jett JR. American College of Chest Physicians. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:69S–77S.CrossRefPubMed
Metadaten
Titel
Non-invasive approaches for lung cancer diagnosis
verfasst von
Aditi Mehta
Guillermo Barreto
Publikationsdatum
18.10.2017
Verlag
Springer Singapore
Erschienen in
Indian Journal of Thoracic and Cardiovascular Surgery / Ausgabe Sonderheft 1/2018
Print ISSN: 0970-9134
Elektronische ISSN: 0973-7723
DOI
https://doi.org/10.1007/s12055-017-0600-4

Weitere Artikel der Sonderheft 1/2018

Indian Journal of Thoracic and Cardiovascular Surgery 1/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.